title: The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis.
abstract: Chronic obstructive pulmonary disease is a common condition which causes considerable morbidity and mortality. It is a heterogenous disorder in which the majority of patients have chronic bronchitis. Bacterial infections are a major cause of acute exacerbations of both conditions which have a major impact on healthcare resources, quality of life and disease progression. Antibiotics are used to treat exacerbations involving purulent sputum production, together with increased breathlessness and/or sputum volume. Moxifloxacin is a quinolone antibiotic and is one of the treatment options. This article discusses pathophysiology of these diseases, moxifloxacin clinical studies and appropriate use of moxifloxacin.
authors.affiliation: Royal Brompton Hospital, London, UK. r.wilson@rbht.nhs.uk
authors.forename: Robert
authors.initials: R
authors.lastname: Wilson
authors.forename: Aislinn
authors.initials: A
authors.lastname: Macklin-Doherty
mesh_terms: D000208:Acute Disease; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D001372:Aza Compounds / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D001991:Bronchitis / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D002908:Chronic Disease; D024841:Fluoroquinolones; D006801:Humans; D000077266:Moxifloxacin; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000382:microbiology / Q000503:physiopathology; D011804:Quinolines / Q000627:therapeutic use*
chemical_list: D000890:Anti-Infective Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D000077266:Moxifloxacin